Prolactinomas
Conditions
Interventions
SDF, FAG/OCT, blood withdrawal including technique that comes with these procedures.
Sponsors
Academic medical center
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients (both women and men) with active micro- or macroprolactinoma and prolactin levels > 40 ng/ml not on prolactin lowering therapy; or 2. Patients (both women and men) with microprolactinoma currently treated with prolactin lowering therapy; 3. Age 18-60 years; 4. Written informed consent.
Exclusion criteria
Exclusion criteria: 1. Retinal disease; 2. Macroprolactinemia; 3. Infundibulum infiltration; 4. Diabetes mellitus type 2; 5. Pregnant women; 6. Premature atherosclerosis; 7. Use of antidepressive and antipsychotic medication; 8. Presence of co-morbidity that could affect retinal vasculature or its matrix; 9. History of hypersensitivity or allergy to fluorescein; 10. Inability to obtain SDF, fluorescein angiograms or OCT’s of sufficient quality to be analyzed and graded; 11. Systemic disease with a life expectancy shorter than the duration of the study; 12. Active malignancy; 13. Inability to adhere to the protocol with regard to injection and follow-up visits; 14. Legally incompetent adult; 15. Refusal to give written informed consent; 16. Additional use of medication that could affect neo-angiogenesis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SDF, OCT, FAG-ICG imaging, will show changes in microcirculation. | — |
Secondary
| Measure | Time frame |
|---|---|
| Coagulation. | — |
Contacts
Public ContactB.M. Sondermeijer
Outcome results
None listed